| Wissenschaftl. Titel | A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response |
| Erkrankung |
Haema:
CML:
Zweitlinie oder später
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (NIH) Weiterführende Informationen (EudraCT) |
erstellt 25.03.2019 Data entry IX CCP
geändert 06.02.2023 Data entry IX CCP